IL124828A0 - Hyaluronic acid receptors binding agents and the use thereof - Google Patents

Hyaluronic acid receptors binding agents and the use thereof

Info

Publication number
IL124828A0
IL124828A0 IL12482896A IL12482896A IL124828A0 IL 124828 A0 IL124828 A0 IL 124828A0 IL 12482896 A IL12482896 A IL 12482896A IL 12482896 A IL12482896 A IL 12482896A IL 124828 A0 IL124828 A0 IL 124828A0
Authority
IL
Israel
Prior art keywords
cac
arg
identified
amino acids
letter code
Prior art date
Application number
IL12482896A
Other languages
English (en)
Original Assignee
Hyal Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyal Pharma Corp filed Critical Hyal Pharma Corp
Publication of IL124828A0 publication Critical patent/IL124828A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/117Esters of phosphoric acids with cycloaliphatic alcohols
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
IL12482896A 1995-12-27 1996-12-23 Hyaluronic acid receptors binding agents and the use thereof IL124828A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002166155A CA2166155C (fr) 1995-12-27 1995-12-27 Liaison d'agents aux domaines de liaison de l'acide hyaluronique et son utilisation
PCT/CA1996/000870 WO1997024111A2 (fr) 1995-12-27 1996-12-23 Agents de liaison des recepteurs d'acide hyaluronique et leur utilisation

Publications (1)

Publication Number Publication Date
IL124828A0 true IL124828A0 (en) 1999-01-26

Family

ID=4157242

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12482896A IL124828A0 (en) 1995-12-27 1996-12-23 Hyaluronic acid receptors binding agents and the use thereof

Country Status (15)

Country Link
EP (1) EP0874624B1 (fr)
JP (1) JP4210330B2 (fr)
KR (1) KR100476782B1 (fr)
AT (1) ATE255411T1 (fr)
AU (1) AU725478B2 (fr)
BR (1) BR9612355A (fr)
CA (1) CA2166155C (fr)
DE (1) DE69630974T2 (fr)
ES (1) ES2211996T3 (fr)
HU (1) HU226598B1 (fr)
IL (1) IL124828A0 (fr)
NO (1) NO982935L (fr)
PL (1) PL327542A1 (fr)
WO (1) WO1997024111A2 (fr)
ZA (1) ZA9610840B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2237051A1 (fr) * 1997-12-19 1999-06-19 Eva A. Turley Affinite amelioree de peptides lies a l'hyaluronan
SE0101854L (sv) * 2001-05-28 2002-11-29 Bioneris Ab Användning av en förening med en negativt laddad region av grupper för behandling av restenos.
WO2004060404A1 (fr) * 2002-12-27 2004-07-22 Chugai Seiyaku Kabushiki Kaisha Vecteur de medicament
CA2610791C (fr) * 2005-06-08 2015-12-01 Cangene Corporation Peptides de liaison a l'acide hyaluronique pour ameliorer les defenses de l'organisme hote contre les bacteries pathogenes
CN106188270A (zh) 2010-05-31 2016-12-07 伦敦健康科学研究中心有限公司 Rhamm结合肽
KR101383941B1 (ko) 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
EP2922869B1 (fr) 2012-11-25 2017-09-27 The Regents of The University of California Peptides qui stimulent l'adipogenèse sous-cutanée
US10844102B2 (en) 2014-05-28 2020-11-24 The Regents Of The University Of California Peptides, compositions, and methods for stimulating subcutaneous adipogenesis
US10562935B2 (en) 2015-03-20 2020-02-18 London Health Sciences Centre Research Inc. Stapled peptides and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340994C (fr) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Traitement de maladies et d'etats pathologiques
CA2122551A1 (fr) * 1994-04-29 1995-10-30 Rudolf Edgar Falk Traitement de l'atherosclerose
GB9207949D0 (en) * 1992-04-09 1992-05-27 Univ Manitoba Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
EP0778776A1 (fr) * 1994-08-30 1997-06-18 Hyal Pharmaceutical Corporation Acide hyaluronique et derives destines a la modulation de l'activite cellulaire

Also Published As

Publication number Publication date
EP0874624B1 (fr) 2003-12-03
AU725478B2 (en) 2000-10-12
WO1997024111A2 (fr) 1997-07-10
NO982935L (no) 1998-08-27
BR9612355A (pt) 1999-12-28
CA2166155A1 (fr) 1997-06-28
DE69630974D1 (de) 2004-01-15
KR100476782B1 (ko) 2005-07-18
WO1997024111A3 (fr) 1997-10-02
ATE255411T1 (de) 2003-12-15
KR19990072058A (ko) 1999-09-27
NO982935D0 (no) 1998-06-24
HU226598B1 (hu) 2009-04-28
AU1091297A (en) 1997-07-28
JP2000506502A (ja) 2000-05-30
CA2166155C (fr) 2008-02-05
HUP9902059A2 (hu) 2000-04-28
ES2211996T3 (es) 2004-07-16
DE69630974T2 (de) 2004-10-28
JP4210330B2 (ja) 2009-01-14
EP0874624A2 (fr) 1998-11-04
ZA9610840B (en) 1997-06-27
HUP9902059A3 (en) 2000-07-28
PL327542A1 (en) 1998-12-21

Similar Documents

Publication Publication Date Title
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
ATE434447T1 (de) Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion
EP0830138A4 (fr) Utilisation de facteurs de croissance des fibroblastes pour stimuler la croissance osseuse
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
WO2001036510A3 (fr) Utilisation de polymeres de poli(diallylamine)
MY118652A (en) Use of diazepines for preparing medicines for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors
CA2184916A1 (fr) Utilisation des facteurs de croissance des fibroblastes pour stimuler la croissance des os
WO2000021548A3 (fr) Dose unitaire de fgf efficace du point de vue angiogenique et methode d'administration
DE69530308D1 (de) Verfahren zur herstellung von dosierungsformen durch feuchtgranulierung
WO1999004772A3 (fr) Levobupivacine et son utilisation
CA2154103A1 (fr) Traitement des maladies, traumatismes ou troubles de la membrane muqueuse, et pour le soulagement de la douleur
ZA9610840B (en) Novel binding agents and the use thereof
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
BR9811755A (pt) Peptìdeo, processo para o tratamento da obesidade em um animal, uso de um peptìdeo, e, composição farmacêutica
IL127044A0 (en) Use of p-aminophenol derivatives for the preparation of pharmaceutical compositions useful in the treatment of neurodegenerative diseases
CA2225788A1 (fr) Agents therapeutiques pour maladies auto-immunes
BR0111002A (pt) Combinação de secretagogos do hormÈnio do crescimento e antidepressivos
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.
YU60199A (sh) Nove soli bpc peptida sa organo-zaštitnom aktivnošću, postupak za njihovo dobijanje i njihova primena u terapiji
EP0743068A3 (fr) Composition pour inhiber la perte osseuse contentant du sulfate de vanadium
EP1039931A4 (fr) Anticorps de recombinaison multivalents destines au traitement d'infections dues au rhinovirus humain (hrv)
BR0005319A (pt) Tratamento combinado para depressão e ansiedade
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired